Yusen Logistics Benelux

Yusen Logistics Benelux is a subsidiary of Yusen Logistics, a global logistics provider with over 60 years of expertise in freight forwarding and transportation. Established in 2011, Yusen Logistics Benelux operates across Belgium, the Netherlands, and Luxembourg, offering comprehensive logistics solutions including warehousing, air and ocean freight, contract logistics, and origin cargo management services. The company serves various industries such as automotive, aerospace, retail, healthcare, technology, and food. (craft.co)

Headquartered in Moerdijk, Netherlands, Yusen Logistics Benelux has multiple facilities in Belgium, including locations in Beveren, Herentals, and Machelen. These facilities enable the company to provide efficient logistics services throughout the Benelux region. (craft.co)

Yusen Logistics Benelux operates a robust distribution network with multiple facilities across Belgium, the Netherlands, and Luxembourg. In Belgium, the company has warehouses in Beveren, Herentals, and Machelen, strategically located to serve various industries, including pharmaceuticals. The company's logistics capabilities encompass air and ocean freight, contract logistics, and origin cargo management services, ensuring efficient supply chain operations. (craft.co)

Yusen Logistics Benelux functions primarily as a logistics intermediary within Belgium's pharmaceutical supply chain. While the company imports finished pharmaceutical formulations from India, it does not engage directly in wholesale distribution or parallel importing. Instead, Yusen Logistics Benelux focuses on providing comprehensive logistics solutions, including warehousing, transportation, and supply chain management services, to facilitate the efficient movement of pharmaceutical products within the region. (craft.co)

Yusen Logistics Benelux's sourcing strategy exhibits a high degree of concentration, with 98.9% of its pharmaceutical imports from India supplied by SUN PHARMACEUTICAL INDUSTRIES LIMITED. This single-source dependency may pose risks related to supply chain disruptions, pricing fluctuations, and regulatory changes affecting the supplier. The company's reliance on a single supplier suggests a strategic choice to leverage established relationships and ensure consistent product quality. However, the limited supplier base may impact the stability of the supply chain, especially in the event of unforeseen disruptions.

The resilience of Yusen Logistics Benelux's Indian supply chain is contingent upon the stability and reliability of SUN PHARMACEUTICAL INDUSTRIES LIMITED. The company's exclusive sourcing from this supplier indicates a deep integration and reliance on their operations. The absence of backup suppliers and limited formulation diversity may expose the supply chain to risks associated with production delays, quality issues, or regulatory challenges affecting the primary supplier. Additionally, the company's shipping routes and regulatory compliance are closely tied to SUN PHARMACEUTICAL INDUSTRIES LIMITED's operations, further emphasizing the need for a robust and resilient supply chain strategy.

Yusen Logistics Benelux's concentrated sourcing strategy positions the company to benefit from strong supplier relationships and potential cost efficiencies. However, the heavy reliance on a single supplier may limit flexibility and responsiveness to market changes. For Indian exporters, this presents an opportunity to diversify their customer base by offering alternative products or formulations that align with Yusen Logistics Benelux's needs, potentially reducing the company's dependency on a single supplier and enhancing supply chain resilience.

In Belgium, the Federal Agency for Medicines and Health Products (FAMHP) is the primary regulatory authority overseeing pharmaceutical imports. The Royal Decree of 4 September 2022, amending the Royal Decree of 19 April 2001, governs the parallel import of medicines for human use. This legislation outlines the conditions and procedures for obtaining a parallel import license, including requirements for marketing authorization in the exporting European Economic Area (EEA) state.

Import licensing in Belgium requires compliance with FAMHP regulations, including obtaining a parallel import license for medicines. Good Manufacturing Practice (GMP) certificates recognized by the European Union (EU), World Health Organization (WHO), or Pharmaceutical Inspection Co-operation Scheme (PIC/S) are essential for ensuring product quality and safety. Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of pharmaceutical products within Belgium.

Pharmaceutical products imported into Belgium must undergo batch testing to verify quality and safety. Stability requirements ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in Dutch, French, and German, providing clear information on usage, dosage, and storage. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Belgium has implemented regulatory changes to facilitate the parallel import of pharmaceuticals. Notably, the Royal Decree of 4 September 2022, effective from 16 September 2022, removed the requirement that the imported medicinal product must have the same therapeutic indications as the Belgian reference product. This amendment simplifies the process for obtaining a parallel import license, potentially increasing the availability of imported medicines in the Belgian market.

Yusen Logistics Benelux's focus on importing finished pharmaceutical formulations, particularly in the gastrointestinal and vitamins & supplements categories, aligns with market demand for these therapeutic areas. The company's imports of esomeprazole, omeprazole, and magnesium reflect a strategic emphasis on products with established efficacy and a broad patient base. This product strategy caters to the prevalent health concerns in Belgium, such as digestive disorders and nutritional deficiencies, ensuring a steady demand for these imported formulations.

Yusen Logistics Benelux's sourcing strategy is centered on importing generic pharmaceutical formulations from India, leveraging the country's robust manufacturing capabilities and cost advantages. The company's preference for finished formulations over active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market products that meet regulatory standards. India's established reputation in pharmaceutical manufacturing positions it as a key supplier for Yusen Logistics Benelux's procurement needs.

Based on its product mix, Yusen Logistics Benelux serves the wholesale distribution segment of the Belgian pharmaceutical market. By importing and distributing finished pharmaceutical formulations, the company plays a crucial role in ensuring the availability of essential medicines to various stakeholders, including retail pharmacies, hospitals, and healthcare providers. Its strategic focus on high-demand therapeutic areas positions it as a key player in meeting the healthcare needs of the Belgian population.

There is a realistic opportunity for new Indian suppliers to engage with Yusen Logistics Benelux, particularly by offering alternative products or formulations that align with the company's import strategy. Diversifying the supplier base can enhance supply chain resilience and reduce dependency on a single source. Identifying gaps in Yusen Logistics Benelux's current sourcing, such as unmet therapeutic needs or emerging market trends, can provide avenues for new suppliers to introduce innovative products that meet the evolving demands of the Belgian pharmaceutical market.

Indian exporters aiming to supply Yusen Logistics Benelux and the Belgian market must ensure compliance with EU GMP standards and obtain the necessary certifications recognized by FAMHP. Products must meet the quality and safety standards stipulated by Belgian regulations, including batch testing and stability requirements. Additionally, labeling must be in the official languages of Belgium—Dutch, French, and German—and adhere to serialization mandates to facilitate traceability and prevent counterfeit products.

Indian exporters should initiate engagement with Yusen Logistics Benelux by demonstrating compliance with EU GMP standards and presenting products that meet the quality and regulatory requirements of the Belgian market. Participating in tenders and responding to requests for proposals can provide opportunities to showcase product offerings. Developing a clear regulatory filing strategy, including obtaining the necessary certifications and approvals, is essential. Establishing a timeline that accounts for regulatory processes, quality assurance procedures, and logistical considerations will facilitate a smooth entry into the Belgian pharmaceutical market.